Evaluation of core decompression outcome in systemic lupus erythematosus with hip osteonecrosis: a retrospective cohort study.
Anti-phospholipid antibodies
Avascular necrosis
Core decompression
Osteonecrosis
Systemic lupus erythematosus
Total hip arthroplasty
Journal
Advances in rheumatology (London, England)
ISSN: 2523-3106
Titre abrégé: Adv Rheumatol
Pays: England
ID NLM: 101734172
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
04
07
2023
accepted:
15
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Osteonecrosis is a major cause of morbidity for patients with systemic lupus erythematosus (SLE). Although core decompression is an approved and trusted technique to prevent further joint deterioration, this surgical method seems to be less beneficial for SLE patients. We aimed to evaluate the outcomes of core decompression in SLE patients with primary stages of femoral head osteonecrosis. In this study, 23 patients (39 affected hip joints) with osteonecrosis of the femoral head with stage II of the disease, based on the Ficat-Arlet classification system, underwent core decompression. Also, patients demographic characteristics, clinical data, medication history, comorbidities, immunological findings, hip plain radiographs, history of total hip arthroplasty after core decompression, and patients satisfaction with joint function according to the Oxford hip score questionnaire were obtained. In the study, 53.8% of affected joints showed signs of radiographic deterioration in follow-up imaging. Sixty-one and a half percent (61.5%) of patients had unsatisfactory joint performance. A third (33.3%) of affected hip joints underwent total hip arthroplasty up to 5 years from core decompression. SLE patients with a history of receiving bisphosphonate were 83.2% less dissatisfied with their joint function than patients without a history of bisphosphonate use (P < 0.02). Of the 23 studied cases, the mean cumulative dose of prednisolone before and after core decompression surgery was 46.41 mg and 14.74 mg respectively. Besides, one case (2.6%) that had a high anti-phospholipid antibodies level during follow-up did not have any radiographic deterioration, and 9 cases (23.1%) had some degrees of radiographic deterioration. The patients group that used bis-phosphonate, had a higher level of satisfaction with joint function after core decompression. Patients with high-level anti-phospholipid antibodies are related to a poor prognosis after core decompression.
Sections du résumé
BACKGROUND
BACKGROUND
Osteonecrosis is a major cause of morbidity for patients with systemic lupus erythematosus (SLE). Although core decompression is an approved and trusted technique to prevent further joint deterioration, this surgical method seems to be less beneficial for SLE patients. We aimed to evaluate the outcomes of core decompression in SLE patients with primary stages of femoral head osteonecrosis.
METHODS
METHODS
In this study, 23 patients (39 affected hip joints) with osteonecrosis of the femoral head with stage II of the disease, based on the Ficat-Arlet classification system, underwent core decompression. Also, patients demographic characteristics, clinical data, medication history, comorbidities, immunological findings, hip plain radiographs, history of total hip arthroplasty after core decompression, and patients satisfaction with joint function according to the Oxford hip score questionnaire were obtained.
RESULTS
RESULTS
In the study, 53.8% of affected joints showed signs of radiographic deterioration in follow-up imaging. Sixty-one and a half percent (61.5%) of patients had unsatisfactory joint performance. A third (33.3%) of affected hip joints underwent total hip arthroplasty up to 5 years from core decompression. SLE patients with a history of receiving bisphosphonate were 83.2% less dissatisfied with their joint function than patients without a history of bisphosphonate use (P < 0.02). Of the 23 studied cases, the mean cumulative dose of prednisolone before and after core decompression surgery was 46.41 mg and 14.74 mg respectively. Besides, one case (2.6%) that had a high anti-phospholipid antibodies level during follow-up did not have any radiographic deterioration, and 9 cases (23.1%) had some degrees of radiographic deterioration.
CONCLUSIONS
CONCLUSIONS
The patients group that used bis-phosphonate, had a higher level of satisfaction with joint function after core decompression. Patients with high-level anti-phospholipid antibodies are related to a poor prognosis after core decompression.
Identifiants
pubmed: 38167574
doi: 10.1186/s42358-023-00345-9
pii: 10.1186/s42358-023-00345-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Informations de copyright
© 2023. The Author(s).
Références
Sadeghi Shaker M, Rokni M, Mahmoudi M, Farhadi E. Ras family signaling pathway in immunopathogenesis of inflammatory rheumatic diseases. Front Immunol. 2023;14:1151246.
doi: 10.3389/fimmu.2023.1151246
pubmed: 37256120
pmcid: 10225558
Sandoughi M, Saravani M, Rokni M, Nora M, Mehrabani M, Dehghan A. Association between COX-2 and 15-PGDH polymorphisms and SLE susceptibility. Int J Rheum Dis. 2020;23(5):627–32.
doi: 10.1111/1756-185X.13808
pubmed: 32100450
Akbarian M, Faezi ST, Gharibdoost F, Shahram F, Nadji A, Jamshidi AR, et al. Systemic lupus erythematosus in Iran: a study of 2280 patients over 33 years. Int J Rheum Dis. 2010;13(4):374–9.
doi: 10.1111/j.1756-185X.2010.01547.x
pubmed: 21199473
Sun HS, Yang QR, Bai YY, Hu NW, Liu DX, Qin CY. Gene testing for osteonecrosis of the femoral head in systemic lupus erythematosus using targeted next-generation sequencing: a pilot study. World J Clin Cases. 2020;8(12):2530–41.
doi: 10.12998/wjcc.v8.i12.2530
pubmed: 32607330
pmcid: 7322418
Mont MA, Salem HS, Piuzzi NS, Goodman SB, Jones LC. Nontraumatic osteonecrosis of the femoral head: where do we stand today?: a 5-year update. J Bone Joint Surg Am. 2020;102(12):1084–99.
doi: 10.2106/JBJS.19.01271
pubmed: 32282421
Lespasio MJ, Sodhi N, Mont MA. Osteonecrosis of the hip: a primer. Permanente J. 2019;23
Jones LC, Hungerford DS. The pathogenesis of osteonecrosis. Instr Course Lect. 2007;56:179–96.
pubmed: 17472306
Chen S, Cai Q, Xu Y, Fu Q, Feng Y, Chen X, et al. Associations between glucocorticoids, antiphospholipid antibodies and femur head necrosis in patients with SLE: a directed acyclic graph-based multicentre study. Therapeutic advances in musculoskeletal disease. 2021;13:1759720X211002677.
Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplast. 2015;30(9):1506–12 e5.
Hussein S, Suitner M, Béland-Bonenfant S, Baril-Dionne A, Vandermeer B, Santesso N, et al. Monitoring of osteonecrosis in systemic lupus erythematosus: a systematic review and metaanalysis. J Rheumatol. 2018;45(10):1462–76.
doi: 10.3899/jrheum.170837
pubmed: 29961688
Faezi ST, Hoseinian AS, Paragomi P, Akbarian M, Esfahanian F, Gharibdoost F, et al. Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: a retrospective case-control study. Mod Rheumatol. 2015;25(4):590–4.
doi: 10.3109/14397595.2014.987366
pubmed: 25528860
Maniwa S, Nishikori T, Furukawa S, Kajitani K, Iwata A, Nishikawa U, et al. Evaluation of core decompression for early osteonecrosis of the femoral head. Arch Orthop Trauma Surg. 2000;120(5–6):241–4.
doi: 10.1007/s004020050456
pubmed: 10853887
Marker DR, Seyler TM, Ulrich SD, Srivastava S, Mont MA. Do modern techniques improve core decompression outcomes for hip osteonecrosis? Clin Orthop Relat Res. 2008;466(5):1093–103.
doi: 10.1007/s11999-008-0184-9
pubmed: 18392909
pmcid: 2311489
Pierce TP, Jauregui JJ, Cherian JJ, Elmallah RK, Mont MA. Imaging evaluation of patients with osteonecrosis of the femoral head. Curr Rev Musculoskelet Med. 2015;8(3):221–7.
doi: 10.1007/s12178-015-9279-6
pubmed: 26045084
pmcid: 4596197
Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60(12):1145–8.
doi: 10.1136/ard.60.12.1145
pubmed: 11709458
pmcid: 1753447
Sadile F, Bernasconi A, Russo S, Maffulli N. Core decompression versus other joint preserving treatments for osteonecrosis of the femoral head: a meta-analysis. Br Med Bull. 2016;118(1):33–49.
doi: 10.1093/bmb/ldw010
pubmed: 27298230
pmcid: 5127418
Ficat R. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surgery Br. 1985;67(1):3–9.
doi: 10.1302/0301-620X.67B1.3155745
Wylde V, Learmonth ID, Cavendish VJ. The Oxford hip score: the patient’s perspective. Health Qual Life Outcomes. 2005;3:1–8.
doi: 10.1186/1477-7525-3-66
Estévez Del Toro M, Varela Ceballos I, Chico Capote A, Kokuina E, Sánchez Bruzón Y, Casas FN. Predictive factors for the development of lupus nephritis after diagnosis of systemic lupus erythematosus. Reumatologia Clinica. 2022;18(9):513–7.
doi: 10.1016/j.reuma.2021.08.004
pubmed: 35523640
Mont MA, Fairbank AC, Petri M, Hungerford DS. Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Orthop Relat Res. 1997;334:91–7.
doi: 10.1097/00003086-199701000-00012
Shaharir SS, Chua SH, Mohd R, Mustafar R, Noh MM, Shahril NS, et al. Risk factors for symptomatic Avascular Necrosis (AVN) in a multi-ethnic Systemic Lupus Erythematosus (SLE) cohort. PLoS ONE. 2021;16(3): e0248845.
doi: 10.1371/journal.pone.0248845
pubmed: 33739994
pmcid: 7978335
Nevskaya T, Gamble MP, Pope JE. A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Experim Rheumatol. 2017;35(4):700–10.
Al Saleh J, El Sayed M, Salah N, Harb D, Khan N, Mohammed N. Predictors of avascular necrosis of the hip in Emiratis patients with systemic lupus erythematosus. Egypt J Immunol. 2010;17(1):29–40.
pubmed: 22053607
Duran-Barragan S, Sandoval-Garcia L, Navarrete-Lorenzon M. Additive risk factors resulting in severe osteonecrosis in systemic lupus erythematosus. Arthritis Rheum. 2010;62(11):3276.
doi: 10.1002/art.27679
pubmed: 20669286
Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997;24(4):654–62.
pubmed: 9101497
Yin J, Weng S, Chen Y, Zhang W, Gao Y. Alendronate prevents glucocorticoid-induced osteonecrosis of the femoral head in rats. Int J Clin Exp Med. 2017;10(7):10133–42.
Paydas S, Balal M, Demir E, Sertdemir Y, Erken U. Avascular osteonecrosis and accompanying anemia, leucocytosis, and decreased bone mineral density in renal transplant recipients. Transpl Proc. 2011;43(3):863–6.
doi: 10.1016/j.transproceed.2011.02.072
Chan KL, Mok CC. Glucocorticoid-induced avascular bone necrosis: diagnosis and management. Open Orthop J. 2012;6:449–57.
doi: 10.2174/1874325001206010449
pubmed: 23115605
pmcid: 3480825
Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet (London, England). 1987;1(8538):902–6.
doi: 10.1016/S0140-6736(87)92870-4
pubmed: 2882300
Shigemura T, Nakamura J, Kishida S, Harada Y, Ohtori S, Kamikawa K, et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology (Oxford). 2011;50(11):2023–8.
doi: 10.1093/rheumatology/ker277
pubmed: 21865285
Gurion R, Tangpricha V, Yow E, Schanberg LE, McComsey GA, Robinson AB. Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatr Rheumatol Online J. 2015;23(13):13.
doi: 10.1186/s12969-015-0008-x